D Wasserberg1, P Jonkheijm1. 1. BIOS Lab-on-a-Chip Group, Molecular Nanofabrication Group of the MESA Institute for Nanotechnology, and Bioinspired Molecular Engineering Laboratory of the TechMed Centre, University of Twente, P.O. Box 217, 7500 AE Enschede, Netherlands.
Essential proteins,
hormones,
and drugs circulate in human blood at concentrations that often do
not exceed picomolar levels, which presents a challenge to existing
sensors. Detection of biomolecules at such ultralow concentrations
can be achieved by miniaturizing bioanalytical and biodiagnostic sensors
by involving nanotechnology and by developing devices with novel transduction
concepts.[1] Miniaturized biosensors are
expected to increase their signal-to-noise ratio due to the high surface-to-volume
ratio, yet mass transfer limitations and insufficient binding affinities
prove severe challenges to achieving and improving ultrasensitive
detection. Most surface-based biosensors require liquid media for
analyte molecules to bind to their complementary receptors immobilized
on the device’s surface. In order to overcome diffusion and
affinity limitations in these biosensors, the binding can be electrically,
magnetically, or optically enhanced.[2] However,
the persistent issue of excessive sample preparation steps or complicated
device structures of existing approaches might have motivated Duan
and co-workers from Tianjin University to search for biocompatible
tools that ensure simple and direct trapping of biomolecules under
physiological conditions.[3]The authors
demonstrate a novel approach to trap and concentrate
proteins by controlling molecular motion via induced flow patterns
using an acoustic nanoelectromechanical system (NEMS) resonator in
both buffer and serum. It is well-known from the hydrodynamic trapping
research in the field of microfluidics that biomolecules in a vortex
flow preferentially migrate from regions of high fluid velocity to
regions where the fluid velocity becomes negligible.[4] Therefore, biomolecules depart from the vortex and accumulate
at the bottom of virtual micropockets, which was conclusively shown
by digital image-plane holographic microscopy.[3] The research team has achieved the concentration factor of 105 by breaking the mass transfer limitation and enhancing the
kinetics of molecular surface binding, which increased the in vitro limit of detection of low-abundance target (bio)molecules
by a factor of up to 1000. A quick and efficient process of protein
concentration could be used in virtually any concept of rapid biomarker
detection and diagnosis. The trapping of biomolecules occurs in open
spaces, and the position of the virtual micropocket, where the biomolecules
are massively trapped and concentrated, is easily predictable by numerical
simulations. These advantages facilitate integration of such devices
into optoelectronic bioassay platforms, as the transducer can easily
be located at, or close to, the virtual micropocket to create a universal
biomolecular concentrator and to enhance real-time label-free biosensing.
The authors have demonstrated the feasibility of this approach by
detecting immunoglobulins and antigens through specific antibody–antigen
interactions using a resonator-enhanced immunoassay integrated into
a biolayer interferometry sensor.[3] In this
device, the acoustic NEMS resonator accumulates the analyte at the
interface of the probe (an optical fiber) to enhance the surface absorption
kinetics of analyte molecules.Schematic representation of an acoustic NEMS resonator as biomolecule
concentrator.In general, this type of device
is biocompatible and can be applied
universally to concentrate molecules or proteins irrespective of their
physical and chemical properties. Further studies should now focus
on the selective trapping of specific proteins that are present in
complex media, such as whole blood. Label-free sensors have the potential
to detect disease markers rapidly, specifically, and sensitively,
providing point-of-care diagnosis at low cost. However, detecting
these biomarkers in physiological fluids will likely be impeded by
common problems such as biofouling and nonspecific binding, and as
a result, the need to use ultrapure reagents and prepurification or
the need to develop multistep sample preparation procedures will challenge
the clinical relevance of any such type of sensor.